Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,616 shares of common stock to cover withholding tax liabilities.
Summary
- On July 5, 2024, Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 3,616 shares of common stock.
- The sale was executed at a price of $0.851 per share.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
- The purpose of the sale was to cover withholding tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Paulson directly owns 1,146,489 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 6
Explanation: The document is neutral. It simply reports a stock sale for tax purposes under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a routine Form 4 filing, indicating insider transactions. It's common for executives to sell shares to cover tax obligations, especially after vesting of stock options or restricted stock units. The existence of a pre-arranged trading plan suggests the sale was not based on current market information.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is likely to be minimal given the reason for the sale and the existence of a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date the reporting person adopted a durable automatic sale instruction plan |
| July 5, 2024 | Date of the transaction (stock sale) |
| July 9, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.